Barclays
PGNX

Barclays’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Barclays’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-73,821
Closed -$280K – 6540
2020
Q1 		$280K Sell
73,821
-343,593
-82% -$1.48M ﹤0.01% 4046
2019
Q4 		$2.12M Buy
417,414
+220,865
+112% +$1.17M ﹤0.01% 2931
2019
Q3 		$993K Sell
196,549
-32,552
-14% -$162K ﹤0.01% 3674
2019
Q2 		$1.41M Buy
229,101
+99,173
+76% +$478K ﹤0.01% 3313
2019
Q1 		$603K Buy
129,928
+67,436
+108% +$305K ﹤0.01% 3940
2018
Q4 		$262K Sell
62,492
-121,843
-66% -$620K ﹤0.01% 4385
2018
Q3 		$1.16M Sell
184,335
-10,171
-5% -$78.1K ﹤0.01% 3490
2018
Q2 		$1.56M Buy
194,506
+101,242
+109% +$773K ﹤0.01% 2801
2018
Q1 		$696K Buy
93,264
+20,578
+28% +$137K ﹤0.01% 3617
2017
Q4 		$433K Sell
72,686
-13,814
-16% -$83.9K ﹤0.01% 4009
2017
Q3 		$637K Buy
86,500
+18,722
+28% +$119K ﹤0.01% 3390
2017
Q2 		$459K Buy
67,778
+3,118
+5% +$23K ﹤0.01% 3616
2017
Q1 		$610K Buy
64,660
+25,305
+64% +$253K ﹤0.01% 3210
2016
Q4 		$340K Buy
39,355
+16,266
+70% +$120K ﹤0.01% 3721
2016
Q3 		$147K Buy
+23,089
New +$140K ﹤0.01% 4219
2016
Q2 		– Sell
-11,892
Closed -$57.4K – 6777
2016
Q1 		$48K Buy
11,892
+6,523
+121% +$29K ﹤0.01% 4801
2015
Q4 		$31K Sell
5,369
-16,117
-75% -$106K ﹤0.01% 5033
2015
Q3 		$107K Sell
21,486
-66,783
-76% -$512K ﹤0.01% 4585
2015
Q2 		$617K Buy
88,269
+6,288
+8% +$38K ﹤0.01% 3301
2015
Q1 		$410K Buy
81,981
+61,632
+303% +$388K ﹤0.01% 3782
2014
Q4 		$143K Buy
20,349
+10,237
+101% +$61.3K ﹤0.01% 4900
2014
Q3 		$51K Sell
10,112
-6,953
-41% -$34.6K ﹤0.01% 5873
2014
Q2 		$68K Sell
17,065
-28,849
-63% -$110K ﹤0.01% 5739
2014
Q1 		$185K Sell
45,914
-13,211
-22% -$67.6K ﹤0.01% 4862
2013
Q4 		$296K Buy
59,125
+23,380
+65% +$103K ﹤0.01% 4615
2013
Q3 		$179K Sell
35,745
-24,574
-41% -$133K ﹤0.01% 5151
2013
Q2 		$269K Buy
+60,319
New +$271K ﹤0.01% 4892

Other funds holding PGNX

ECM
Everence Capital Management Goshen, Indiana $1.64B AUM 26.46% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $49.2B AUM 29.3% 1-Year Est. Return
Daiwa Securities Group
Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Barclays's PGNX Position: Q2 2020 in Review

Barclays sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 73,821 shares — an estimated $280K sold.

Barclays first reported a position in PGNX in Q2 2013 and held it in 27 quarters. The position peaked at $2.12M in Q4 2019. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.

  • Barclays reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
  • Barclays sold 73,821 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $280K.
  • Barclays first reported a position in Progenics Pharmaceuticals Inc in Q2 2013 and held it in 27 quarters.
  • Barclays's Progenics Pharmaceuticals Inc position peaked at $2.12M in Q4 2019.
  • 3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.

Based on Barclays's 13F filing for Q2 2020, filed 12 Aug 2020.